TraceLink and Advanco partner to simplify serialization line management integration
Partnership to collaborate with industry to reduce risk and ensure optimal compliance for all members of the pharmaceutical supply chain.
TraceLink has partnered with Advanco to support pharmaceutical manufacturers with the integration of line management and enterprise systems when complying with new serialization regulations.
The agreement will see TraceLink resell Advanco’s ARC Suite software, an industry-leading software solution that integrates packaging lines and enterprise serialization repositories. It will allow pharmaceutical and contract manufacturing companies to utilize multiple line management systems, providing purchasing flexibility, while also simplifying integration with the TraceLink Life Sciences Cloud at the enterprise and network level for serialization.
As the leading provider for enterprise and network system Levels 4 and 5, TraceLink will offer the Advanco ARC Suite software to customers looking for a consistent global site server solution that is independent of the Line Management System (LMS).
“Pharmaceutical and contract manufacturers continue to face a number of challenges in synchronizing multiple interconnected packaging levels in order to comply with serialization regulations. TraceLink and Advanco recognized the need to provide a flexible option for the industry to cut down on time-consuming and costly integrations between line management and enterprise systems and efficiently comply with serialization regulations,” said Shabbir Dahod, president and CEO of TraceLink.
“TraceLink is partnering with the industry’s leading companies, such as Advanco, to deliver flexible, scalable solutions, quality implementation services and proven production integrations to its customers. These partnerships supplement our ongoing and active involvement with interoperability standards and industry workgroups such as Open-SCS and GS1, which demonstrate TraceLink’s commitment to working collaboratively with industry to reduce risk and ensure optimal compliance for all members of the pharmaceutical supply chain."
ARC Suite will streamline integration across all LMS solutions and remove any restrictions associated with purchasing from multiple line vendors resulting from implementing a proprietary site server. This simplified, interoperable approach through TraceLink and Advanco will allow manufacturers to leverage any combination of line management solutions, while improving procurement and deployment flexibility.
Olgun Yenersoy, founder and CEO of Advanco added: “TraceLink is the global leader in serialization and track and trace at the enterprise level because its proven Life Sciences Cloud serialization platform enables more than 500 pharmaceutical manufacturers, CMOs, distributors, 3PLs and dispensers to exchange data with over 248,000 supply chain partners. The TraceLink and Advanco integration offers true simplicity in system integration and will help facilitate smoother deployment of serialization solutions for all packaging levels. We look forward to this partnership with TraceLink and working collaboratively to help the industry achieve compliance in the EU, US and other global markets.”
Eric Tjoa, CEO of Tjoapack, commented: “As a customer of both TraceLink and Advanco, we’re able to offer easy integration across all line levels, well ahead of the US and EU deadlines, while continuing to guarantee the highest quality of services for our customer base. The partnership between TraceLink and Advanco gives us increased flexibility, particularly for our customers that need options for leveraging different line management strategies, ranging from a single system to several large line management systems. Seamless integration is a core component to success for serialization and an integral factor for pharmaceutical manufacturers to achieve compliance on time.
“We are thrilled about this partnership and will be discussing the benefits of simplified line-level integration with both companies at our upcoming serialization event on 30 March at Tjoapack headquarters.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance